160 patents currently held
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Oct 2027
Next term end
73
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2034 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Jul 2032 · High confidence
Sequence Specific Antimicrobials
US 10,660,943
The most cited patent in this portfolio, cited by 171 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2034.
System and Method for Optical Detection of Skin Disease
US 10,182,757
Cited by 81 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2034.
Antibodies Directed Toward the HIV-1 GP120 CD4 Binding Site with Increased Potency and Breadth.
US 9,493,549
Cited by 68 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends no later than Dec 2033 · Low confidence
The most cited patent in this portfolio, cited by 383 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Massachusetts Institute of Technology
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Nov 19 to 28, 2026 · next Nov 19
- 3 fees due Dec 2 to 13, 2026 · next Dec 2
- 2 fees due Jan 4 to 14, 2027 · next Jan 4
- 2 fees due Feb 27, 2027
- 6 fees due Mar 8 to 24, 2027 · next Mar 8
- 1 fee due Apr 27, 2027The maintenance fee for Modified RNA Ligase for Efficient 3' Modification of RNA (US 9,169,507) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 2 fees due May 7 to 28, 2027 · next May 7
- 4 fees due Jul 9 to 28, 2027 · next Jul 9
- 8 fees due Sep 5 to 29, 2027 · next Sep 5
Recent changes
- Nov 3Assignment recorded on 1 record: Perez-Mitta, Gonzalo and 1 other to The Rockefeller University Recorded Nov 3, 2026, executed Feb 28, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76608, frame 174.
- 2 of the patents on this record were granted since Aug 19, 2026
- 4 terms have ended since Aug 19, 2026
What they patent
The 5 largest of its 73 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified RNA Ligase for Efficient 3` Modification of RNA | 19 in force | to Sep 2043 |
| Sequence Specific Antimicrobials | 12 in force | to May 2034 |
| Streptococcus Bacteriophage Lysins for Detection and Treatment of Gram Positive Bacteria | 10 in force | to Nov 2032 |
| Treatment of Drug Resistant Cancer | 8 in force | to Apr 2034 |
| Non-Sialylated Anti-Inflammatory Polypeptides | 7 in force | to Dec 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,532,980 | Methods for the Treatment of A-Beta Related Disorders and Compositions Therefor In force · High confidence | In force | High confidence | |
| US 9,169,507 | Modified RNA Ligase for Efficient 3' Modification of RNA In force · High confidence | In force | High confidence | |
| US 8,809,022 | Modified RNA Ligase for Efficient 3` Modification of RNA In force · High confidence | In force | High confidence | |
| US 8,470,318 | Polypeptides with Enhanced Anti-Inflammatory and Decreased Cytotoxic Properties and Relating Methods In force · High confidence | In force | High confidence | |
| US 7,846,744 | Methods of Identifying Anti-Inflammatory Compounds In force · High confidence | In force | High confidence | |
| US 11,015,182 | Chimeric Bacteriophage Lysin with Activity Against Staphylococci Bacteria In force · High confidence | In force | High confidence | |
| US 11,827,911 | Chimeric Bacteriophage Lysin with Activity Against Staphylococci Bacteria In force · High confidence | In force | High confidence | |
| US 8,383,370 | Modified RNA Ligase for Efficient 3` Modification of RNA In force · High confidence | In force | High confidence | |
| US 8,703,707 | Nucleobindin I Variant Protein Compositions and Methods of Use In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,134,310 | Methods of Identifying Anti-Inflammatory Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 160: 17 patents in force now held by others · 103 patents ended · 73 applications pending · 158 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.